SPY328.87+2.35 0.72%
DIA266.70+2.35 0.89%
IXIC10,888.42+143.14 1.33%

Leap Therapeutics And BeiGene Announce Exclusive Option And License Agreement For DKN-01; Initiation Of Combination Studies Of Leap's DKN-01 With Beigene's Anti-PD-1 Antibody Tislelizumab Planned

Benzinga · -